S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

HLS Therapeutics Stock Forecast, Price & News

-0.19 (-1.25%)
(As of 01/19/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
14,446 shs
Average Volume
15,601 shs
Market Capitalization
C$486.77 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HLS Therapeutics logo

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.


See More Headlines

Industry, Sector and Symbol

Drug Manufacturers - Specialty & Generic
Year Founded

Sales & Book Value

Annual Sales
C$60.80 million
Cash Flow
C$0.69 per share
Book Value
C$5.08 per share


Pretax Margin




Free Float
Market Cap
C$486.77 million
Not Optionable

Company Calendar

Ex-Dividend for 12/15 Dividend
Last Earnings
Dividend Payable
Ex-Dividend for 3/15 Dividend
Dividend Payable
Next Earnings (Estimated)


Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

HLS Therapeutics (TSE:HLS) Frequently Asked Questions

Is HLS Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLS Therapeutics stock.
View analyst ratings for HLS Therapeutics
or view top-rated stocks.

How has HLS Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

HLS Therapeutics' stock was trading at C$18.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HLS shares have decreased by 20.0% and is now trading at C$15.00.
View which stocks have been most impacted by COVID-19

When is HLS Therapeutics' next earnings date?

HLS Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for HLS Therapeutics

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) announced its earnings results on Thursday, November, 4th. The company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.07. The firm had revenue of $18.96 million for the quarter, compared to analysts' expectations of $19.56 million.
View HLS Therapeutics' earnings history

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics declared a quarterly dividend on Wednesday, November 3rd. Shareholders of record on Friday, January 28th will be given a dividend of 0.05 per share on Tuesday, March 15th. This represents a $0.20 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Thursday, January 27th.
View HLS Therapeutics' dividend history

Is HLS Therapeutics a good dividend stock?

HLS Therapeutics pays an annual dividend of C$0.16 per share and currently has a dividend yield of 1.32%.
View HLS Therapeutics' dividend history.

What price target have analysts set for HLS?

4 brokerages have issued twelve-month target prices for HLS Therapeutics' shares. Their forecasts range from C$26.00 to C$36.00. On average, they expect HLS Therapeutics' share price to reach C$31.33 in the next year. This suggests a possible upside of 108.9% from the stock's current price.
View analysts' price targets for HLS Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 60, Pay $587.15k)
  • Mr. Gilbert Godin, Co-Founder, Pres, CEO & Director (Age 62, Pay $800.32k)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder & Director (Age 64, Pay $1.93M)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 49, Pay $356.14k)
  • Mr. Sanjiv Sharma, Chief Commercial Officer (Age 65, Pay $460.14k)
  • Dr. Hemanth Jacob Varghese, Sr. VP of Strategy & Operations (Age 45, Pay $382.25k)
  • Mr. Ryan C. Lennox B.A., J.D., Sr. Vice-Pres of Legal, HR & Compliance and Corp. Sec. (Age 40)
  • Ms. Patricia Perry, Vice-Pres Human Resource
  • David Spence, Corp. Controller (Age 53)

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS).

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

How do I buy shares of HLS Therapeutics?

Shares of HLS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is HLS Therapeutics' stock price today?

One share of HLS stock can currently be purchased for approximately C$15.00.

How much money does HLS Therapeutics make?

HLS Therapeutics has a market capitalization of C$486.77 million and generates C$60.80 million in revenue each year.

How many employees does HLS Therapeutics have?

HLS Therapeutics employs 88 workers across the globe.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is www.hlstherapeutics.com.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.